Salk Institute for Biological Studies
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Salk Institute for Biological Studies
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2015.
- Academic and Research Institutions